STOCK TITAN

Bon Natural Life forms joint lab with China Oat Group

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Bon Natural Life Ltd (BON) announced the establishment of the BON Natural Ingredients and Biomanufacturing Joint Laboratory with China Oat Group Co., Ltd., through BON subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd. The joint lab will focus on biomanufacturing high-value natural ingredients, using synthetic biology as its foundation and AI as a key competitive differentiator.

The partners aim to develop biomanufacturing technologies for oat-derived ingredients, addressing supply availability, supply stability and production costs. The lab will also work on quality standards, including systematic testing and validation of ingredient purity, safety, and elemental and isotopic profiles.

China Oat Group invention patents More than 10 patents China Oat Group holds more than ten invention patents in China.
synthetic biology technical
"synthetic biology serving as its technological foundation"
Synthetic biology is the design and construction of new or modified living systems—like reprogramming cells or microbes—to perform useful tasks such as making materials, medicines, or fuels. For investors it signals a platform technology with potential for high growth and disruption, similar to how software transformed industries: early breakthroughs can create new markets, long-term revenue streams, and also carry technical, regulatory, and ethical risks that affect valuation and timing.
biomanufacturing technical
"biomanufacturing of natural ingredients"
Making medicines, vaccines and other products using living cells or biological systems instead of purely chemical processes; it is the industrial-scale “cooking” of biological ingredients into finished medical products. Investors care because biomanufacturing determines how quickly and cheaply a company can deliver therapies, meet demand, pass regulatory checks and protect earnings—like a bakery’s ovens and recipes deciding how much bread it can sell and at what cost.
beta-glucan medical
"bioactive compounds such as beta-glucan"
A class of naturally occurring polysaccharides composed of glucose molecules linked primarily by beta-glycosidic bonds, found in the cell walls of cereals (like oats and barley), yeasts, fungi, and some bacteria. As a soluble dietary fiber, beta-glucans can lower blood cholesterol by binding bile acids in the gut, and certain structural forms also interact with immune-system receptors to modify immune responses; the biological effects depend on molecular structure and source, so potency and regulatory classification vary by preparation.
avenanthramides (AVAs) medical
"beta-glucan and avenanthramides (AVAs)"
elemental and isotopic profiles technical
"ingredient purity, safety, and elemental and isotopic profiles"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BON announce with China Oat Group?

BON and China Oat Group announced the establishment of a joint laboratory focused on natural ingredients and biomanufacturing. The collaboration was announced at a symposium convened by BON subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd.

How many patents does China Oat Group hold?

China Oat Group holds more than ten invention patents in China, along with multiple patents in the United States, Europe, Canada, Australia and other markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number 001-40517

 

BON NATURAL LIFE LIMITED

(Translation of registrant’s name into English)

 

Room 601, Block C, Gazelle Valley, No.69, Jinye Road

High-Tech Zone, Xi’an, Shaanxi, China

People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 
 

 

Attached hereto and incorporated herein is the Registrant’s press release issued on November 20, 2026, titled “BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation.”

 

Exhibits

 

The following exhibit is included in this Form 6-K:

 

Exhibit No.   Description of Exhibit
99.1   Press release titled “BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation.”

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 20, 2026 Bon Natural Life Limited
     
  By: /s/ Yongwei Hu
    Yongwei Hu
    Chairman and Chief Executive Officer

 

 

 

Exhibit 99.1

 


BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation

 

XIAN, China, Nov. 20, 2026 /PRNewswire/ — Bon Natural Life Limited (NASDAQ: BON) (“BON” or the “Company”), a leading provider of bio-ingredient solutions for the natural, health, and personal care industries, today announced that its subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd. (“App-Chem”) recently convened a symposium with China Oat Group Co., Ltd. (“China Oat Group”) on the theme of “Advancing the High-Quality Development of China’s Health Industry”. At the event, the two parties announced the establishment of the BON Natural Ingredients and Biomanufacturing Joint Laboratory (the “BON Joint Lab” or the “Joint Lab”).

 

Through an innovative collaboration model, the BON Joint Lab aims to build an integrated innovation framework spanning the entire value chain, from fundamental research and pilot-scale development to standard-setting and industrial commercialization. The Joint Lab will focus on developing an AI-driven technological platform for the biomanufacturing of natural ingredients, with synthetic biology serving as its technological foundation and artificial intelligence (AI) as a key competitive differentiator. Its primary focus will be the development of biomanufacturing technologies for high-value natural ingredients. This integrated technological framework is expected to enhance the Joint Lab’s competitive position in the natural ingredients biomanufacturing sector while offering the industry new alternatives to conventional production methods.

 

Oats are widely recognized for their nutritional value and health benefits. They contain bioactive compounds such as beta-glucan and avenanthramides (AVAs), which have demonstrated various biological activities, including cardiovascular protection, blood glucose regulation, antioxidant effects, and anti-inflammatory properties. As a supplier of oat-based health products, China Oat Group serves a market characterized by strong demand and significant growth potential. However, limited availability of natural raw materials and high sourcing costs have constrained the broader commercial application and market expansion of oat-derived products.

 

Through the establishment of the Joint Lab, BON and China Oat Group aim to develop biomanufacturing technologies for oat-derived natural ingredients, with the goal of fundamentally addressing challenges related to supply availability, supply stability, and high production costs. BON and China Oat Group believe that this initiative is of significant importance in expanding the market for oat-derived natural ingredients.

 

Standards development plays a critical role in the biomanufacturing of natural ingredients. The unique complexity of natural ingredient sourcing, heightened regulatory scrutiny of product safety, and distinct consumer preferences for naturally derived ingredients make the establishment of standards for biomanufactured natural ingredients critically important to their commercial value.

 

BON and China Oat Group have undertaken extensive and productive work in developing quality standards for natural ingredients. The Joint Lab will make standards development a dedicated area of focus, conducting systematic testing and validation of key parameters, including ingredient purity, safety, and elemental and isotopic profiles. Through a comprehensive and integrated process of evaluation and optimization, the Joint Lab aims to establish systematic differentiation in product standards across multiple dimensions, including safety, differentiated quality standards, and similarity to naturally derived counterparts.

 

BON has established a strong presence in the natural ingredients biomanufacturing sector and has articulated its vision of becoming an “AI-driven pioneer in digital nutrition”. The Company is committed to accelerating the transition from conventional natural extraction methods to AI-driven biomanufacturing. The Company believes that it has built a strong technological foundation in natural products, biosynthesis, and the application of AI in biology, supported by robust industrialization capabilities and global market development expertise.

 

 
 

 

China Oat Group has developed extensive expertise across the entire oat value chain and holds more than ten invention patents in China, along with multiple patents in the United States, Europe, Canada, Australia, and other markets. Leveraging its advanced technologies in areas such as oat protein enzymatic hydrolysis and the preservation of beta-glucan bioactivity, China Oat Group has developed a portfolio of oat-based nutritional products whose health benefits have been evaluated through medical research. China Oat Group was also among the first companies to achieve large-scale, standardized deep processing of oats, with its related technologies receiving authoritative certifications in Europe and the United States.

 

Mr. Yongwei Hu, Chairman of BON, commented, “Our strategic collaboration with China Oat Group marks a pivotal step in our efforts to establish a stronger presence in the core natural ingredients sector, accelerate our expansion into the rapidly growing global biomanufacturing market, and further strengthen our position as an innovation leader in the industry. Through the Joint Lab, we aim to advance cutting-edge research in areas such as the biosynthesis of high-value natural ingredients, the discovery of functional bioactive compounds, and precision nutrition interventions. We are committed to accelerating the commercialization of scientific and technological innovations and delivering a broader range of safe and effective health solutions to consumers. Through the disciplined execution of our technology-driven business strategy, we seek to unlock significant commercial value and generate sustainable returns for our investors.”

 

About Bon Natural Life Limited (“BON”)

 

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.

 

For more information, please contact:

Cindy Liu | IR

Email: bonnatural@appchem.cn

 

Safe Harbor Statement

 

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

 

 



Filing Exhibits & Attachments

1 document

Keep reading